Skip to content

Hydration strategy of percutaneous coronary intervention in patients with chronic heart failure and chronic kidney disease

Hydration strategy of percutaneous coronary intervention in patients with chronic heart failure and chronic kidney disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000039912
Enrollment
Unknown
Registered
2020-11-14
Start date
2020-11-30
Completion date
Unknown
Last updated
2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contrast induced acute kidney injury

Interventions

Semi-Hydration Group:Hydration rate 0.5 mL/Kg/h
Standard Hydration group:Hydration rate 1 mL/Kg/h
Hydrated Diuretic group:Hydration rate 1 mL/Kg/h + Furosemide 20 mg diuresis immediately after intervention

Sponsors

Department of Cardiology, The Second Hospital of Tianjin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Patients who have indications for coronary intervention and plan to receive coronary angiography or coronary stent implantation; 2. Patients with high risk of ci-aki: Patients with chronic heart failure and chronic kidney disease. Chronic heart failure is defined as: Heart failure with reduced ejection fraction: (1) There were definite symptoms and signs of heart failure; (2) Left ventricular ejection fraction 2 or < 1); Chronic kidney disease is defined as patients with glomerular filtration rate between 15-60 ml / min.

Exclusion criteria

Exclusion criteria: 1. Patients with glomerular filtration rate less than 15 ml / min, or patients requiring long-term hemodialysis or peritoneal dialysis; 2. Patients with acute myocardial infarction who plan to undergo emergency PCI; 3. Patients with acute and chronic infection; 4. Patients with coagulation dysfunction; 5. Patients allergic to furosemide, sulfonamides and thiazides; 6. Uncontrolled grade 3 hypertension or severe hypotension (systolic blood pressure below 90mmHg); 7. Patients with malignant tumor; 8. Pregnancy; 9. Patients with acute diabetic complications such as ketoacidosis or lactic acidosis; 10. Patients with other clinical conditions causing acute renal damage; 11. Patients who were assessed to be intolerant of the intervention and did not sign the informed consent.

Design outcomes

Primary

MeasureTime frame
Contrast induced acute kidney injury;

Secondary

MeasureTime frame
Major adverse cardiovascular events during hospitalization and within 30 days;

Countries

China

Contacts

Public ContactHao Zhang

Department of Cardiology, Second Hospital of Tianjin Medical University

haixin08@126.com+86 13920348832

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026